This is a working overview of GIP receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-16. Anything still debated is marked as such rather than presented as settled.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
European Union officials, European ministers and Commissioner (Tonio) Borg set up an urgent meeting in Brussels on 13 February 2013 on how to contain the horse meat scandal that exposed flaws in European control systems on food safety, and to formulate an action plan. Following the meeting, EU agriculture ministers announced a three-month coordinated control plan of DNA testing of processed meat across the European Union. The plan, adopted 19 February 2013, called for 2,500 random tests on processed food for horse DNA and 4,000 for phenylbutazone (bute), beginning in March 2013, with initial results announced on 15 April 2013. The Hague-based Europol would handle the co-ordination of investigations among national authorities, as well as any raids on premises and arrests on suspicion of criminal conspiracy to defraud.
The Medic class is equipped with a super nail gun, concussion grenades and a medical kit that can be used either to heal teammates or expose opponents to a contagious infection that drains health. The Heavy Weapons class is armed with a powerful minigun, and can sustain more damage than any other class. However, the Heavy is significantly slower than the other classes. The Pyro class is equipped with a flamethrower and an incendiary rocket launcher, both of which can set enemies on fire. Pyros also carry several napalm grenades for the same purpose. The Spy class differs significantly in style from other classes, as he can disguise himself to look like any other class on either side. The Spy is equipped with a knife to kill enemy players in one hit by stabbing them in the back, a tranquilizer gun to slow down opponents and a hallucination grenade which spouts gas to confuse them. Spies also possess the ability to feign death, allowing them to use their backstab ability more effectively. The Engineer class builds structures to support their team, such as sentry guns to defend key points, ammunition dispensers and teleporters. Engineers have the ability to replenish a teammate's armor by tapping them with their wrench. In addition, the Engineer is armed with EMP grenades that detonates any explosive ammunition within its range, as well as a shotgun for backup.
== History == Dated back to 1956, the first protein modified transition metal catalyst was documented. The Palladium(II) salt was absorbed onto silk fibroin fiber, reduced by hydrogen to get the first reported ArM, which can catalyze asymmetric hydrogenation. This work was not reproducible, but it is considered to be the first work in the field of artificial metalloenzymes. At that time, the major challenge that blocked further studies was underdeveloped protein production and purification technology. The first attempt to anchor an abiotic metal center onto a protein was reported by Whitesides et al. using biotin-avidin interaction, making an artificial hydrogenase. The presence of avidin can significantly increase the catalytic capacity of Rhodium(I) cofactor in aqueous phosphate buffer. Another pioneering work was conducted by Kaiser et al. where carboxypeptidase A (CPA) was repurposed into an oxidase by substituting Zn(II) center by Cu(II), for the oxidation of ascorbic acid. The real potential of ArMs was unleashed when recombinant protein production was developed, namely in 1997 Distefano and Davies reported a scaffold modification of a recombinant adipocyte lipid-binding protein (ALBP) with iodoacetamido-1,10-phenanthroline coordinating Cu(II) for the stereoselective hydrolysis of racemic esters.
=== Gómez, France 1998 and the end of the cycle (1995–1999) === Hernán Darío Gómez, known as El Bolillo, replaced Maturana in 1995. Colombia lost 2–0 to the hosts Uruguay in the semi-finals of the 1995 Copa América before beating the United States 4–1 in Maldonado to take third place, Wilmer Cabrera, Valderrama, Asprilla and Rincón all scoring. Two years later they were eliminated 2–1 by the hosts Bolivia in the quarter-finals of the 1997 Copa América. Colombia reached the 1998 FIFA World Cup by finishing third in the first CONMEBOL qualifying tournament contested as a single home-and-away league, taking 28 points from sixteen matches — two behind Argentina and one behind Paraguay — with Asprilla their leading scorer on seven goals, including a hat-trick in a 4–1 win over Chile in Barranquilla. Drawn in Group G with Tunisia, England and Romania, they lost 1–0 to Romania, beat Tunisia 1–0, and were eliminated on 26 June by England at the Stade Bollaert-Delelis in Lens. Darren Anderton volleyed England ahead in the 20th minute and David Beckham curled in a free kick from some 30 yards nine minutes later for his first international goal, Faryd Mondragón keeping the margin to 2–0 thereafter.
== Education == Lectka completed his bachelor's in chemistry and graduated from Oberlin College in 1985. He completed his doctoral degree in organic chemistry from Cornell University in 1991. He then completed his postdoctoral studies as an Alexander von Humboldt Postdoctoral Fellow at the University of Heidelberg in Germany and then as a National Institutes of Health Postdoctoral Fellow at Harvard University.
Sources: en.wikipedia.org
== Further reading == Moses HL, Roberts AB, Derynck R (July 2016). "The Discovery and Early Days of TGF-β: A Historical Perspective". Cold Spring Harbor Perspectives in Biology. 8 (7) a021865. doi:10.1101/cshperspect.a021865. PMC 4930926. PMID 27328871.
5,10-methylene tetrahydrofolate is used to convert dUMP to dTMP for de novo thymidine synthesis. 5-Methyltetrahydrofolate is used to convert homocysteine (a potentially toxic amino acid) to methionine by the enzyme methionine synthase. (Note that homocysteine can also be converted to methionine by the folate-independent enzyme betaine-homocysteine methyltransferase (BHMT).) MTHFR contains a bound flavin cofactor and uses NAD(P)H as the reducing agent.
Breath testing is a widespread method for quickly determining alcohol intoxication. A breath test measures the alcohol concentration in the body by a deep-lung breath. There are different instruments used for measuring the alcohol content of an individual though their breath. A Breathalyzer is a widely known instrument which was developed in 1954 and contained chemicals unlike other breath-testing instruments. More modern instruments include infrared light-absorption devices and fuel cell detectors. To get accurate readings on a breath-testing device the individual must blow for approximately 6 seconds and need to contain roughly 1.1 to 1.5 liters of breath. For a breath test to provide an accurate result an operator must take steps such as avoiding measuring "mouth alcohol" which is a result from regurgitation, belching, or recent intake of an alcoholic beverage. To avoid measuring "mouth alcohol" the operator must not allow the individual being tested to consume any materials for at least fifteen minutes before the breath test. In the United States, a driver who refuses to take a breath test can have their driver's license suspended for a period of 6 to 12 months.
Player was born in Johannesburg, South Africa, the youngest of Muriel and Harry Player's three children. At age 17, he became a professional golfer. Player married wife Vivienne Verwey (sister of professional golfer Bobby Verwey) on 19 January 1957, four years after turning professional. Together they had six children: Jennifer, Marc, Wayne, Michele, Theresa, and Amanda. He also has 22 grandchildren and two great-grandchildren. During the early days of his career, Player would travel from tournament to tournament with his wife, six children, their nanny and a tutor in tow. Vivienne died of cancer in August 2021. Player's eldest son, Marc, owns and operates The Player Group, including all trademarks and intellectual property. The Player Group exclusively represents Player in all his commercial activities, including all endorsements, licensing, merchandising, golf course design, and real estate development. In 2020, Player won a legal battle against the Gary Player Group. He was awarded $5 million and the rights to his name and likeness back from the company. Today, the Gary & Vivienne Player Foundation (established after Vivienne's death in 2022) operates in South Africa and the United States. Player is the brother of Ian Player, a South African environmental educator, activist and conservationist.
APHL monitors trends in public health laboratory diagnostics, personnel and infrastructure. It uses this data to benchmark against national norms and to define issues of importance to lab practice and policy. APHL also disseminates research findings via issue briefs and communications with federal decision makers, health partners and the laboratory community. Members have access to survey data online, enabling them to leverage this information quickly to identify promising strategies and practices. In an effort to improve laboratory practice, APHL provides free resources, such as tools kits that explain how to: Write a laboratory quality manual Conduct an internal audit Recruit students in STEM fields Deal with laboratory floods In addition to on-demand research and reports, APHL provides continuing education courses to help laboratory scientists keep up with emerging trends, and innovative testing techniques. Training sessions are conducted through conferences, seminars, workshops and online courses.
Sources: en.wikipedia.org
Comparative genomics approaches were used to predict the function-relevant variants under the assumption that the functional genetic locus should be conserved across different species at an extensive phylogenetic distance. On the other hand, some adaptive traits and the population differences are driven by positive selections of advantageous variants, and these genetic mutations are functionally relevant to population specific phenotypes. Functional prediction of variants' effect in different biological processes is pivotal to pinpoint the molecular mechanism of diseases/traits and direct the experimental validation.
The isotopes 280Rg and 281Rg are promising for chemical experimentation and may be produced as the granddaughters of the moscovium isotopes 288Mc and 289Mc respectively; their parents are the nihonium isotopes 284Nh and 285Nh, which have already received preliminary chemical investigations.
29 November Astronomers report the discovery of a star, HD 110067, that contains six sub-Neptune exoplanets with radii ranging from 1.94R⊕ to 2.85R⊕. The first example of a planet-forming disk beyond the Milky Way galaxy is reported by astronomers using the ALMA in Chile. The system, designated as HH 1177, is located in the Large Magellanic Cloud, about 160,000 light years away. 30 November Researchers demonstrate multicellular microbots grown from a human cell, "anthrobots", that can move around in tissues in vitro. A trial comparing a healthy vegan and a healthy omnivorous diet in identical twins finds the former to be substantially better according to cardiometabolic measures like LDL-C after 8 weeks. Promising innovations relating to global challenges are reported: an efficient electrocaloric heat pump for sustainable cooling (16 Nov), taste-tested bioreactor-grown cultured coffee (17 Nov), an autonomous laboratory for synthesis of inorganic powders, the A-Lab (29 Nov), a solar tower design using downdraft technology for hot and dry weather areas that could generate twice the electricity of solar updraft systems and operate at night, the Twin-Technology Solar System (TTSS) (30 Nov). Promising results of health and medical research are reported: phase 2-trialed Mazdutide against type-2 diabetes (9 Nov), phase 1-trialed lepodisiran against cardiovascular risk factor lipoprotein (12 Nov), rat-tested depot technology for sustained delivery of GLP-1 receptor agonists against the need for frequent injections (21 Nov).
Hashim Thaçi (born 24 April 1968) is a Kosovan politician who was the first prime minister of Kosovo (2008–2014) and the foreign minister and deputy prime minister (2014–2016) in the cabinet led by Isa Mustafa. He also served as president of Kosovo from 2016 until his resignation in 2020. Thaçi is from the region of Drenica in Kosovo, which is where the Kosovo Liberation Army (KLA) originated. He studied philosophy in Pristina before moving to Switzerland, where he joined the KLA in 1993. An Albanian nationalist, he rose through the ranks of the KLA to become leader of the most powerful faction by 1999, during the Rambouillet negotiations. He then joined the interim Kosovo administration after the war. Thaçi became leader of the Democratic Party of Kosovo (PDK), which won the largest share of the vote in the 2007 Kosovo elections. In 2008, Thaçi read the declaration of independence of Kosovo and became its first prime minister. In 2016 he was elected president of Kosovo. Thaçi pursued a pro-American policy while in office. In September 2026, Thaçi was convicted by the Kosovo Specialist Chambers' first instance Trial Panel of war crimes in the Kosovo War. Thaçi's defence lawyers stated that they would appeal the decision. In 2020, the Kosovo Specialist Chambers and Specialist Prosecutor's Office in The Hague filed a ten-count indictment against Thaçi and others, charging them with crimes against humanity and war crimes. To face these charges, Thaçi resigned from the presidency, stating that he did so to "protect the integrity of the presidency of Kosovo".
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.